Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms

NCT00160472CompletedNAINTERVENTIONAL

Summary

This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. The investigators will examine whether AVP protein and AVP and V1 receptor mRNA expression vary with respect to tumor histology, intratumoral vascularization and systemic blood pressure.

Key Facts

Lead Sponsor

United States Department of Defense

Enrollment

110

Start Date

2004-03-01

Completion Date

2009-01-01

Study Type

INTERVENTIONAL

Official Title

Evaluation of Vasopressin and Vasopressin Receptor Expression in the Arteries and Veins of Ovarian Neoplasms

Interventions

removal of ovarian vessels

Conditions

Ovarian Neoplasms

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* All patients who have had gynecologic tissue removed for benign (noncancerous) or malignant (cancerous) indications.

Exclusion Criteria:

* Patients who have a malignancy that is not a primary gynecologic malignancy.
* Age less than 18
* Males

Outcome Measures

Primary Outcomes

Compare the levels of AVP and the vasopressin V1 receptor expression in the arteries and veins of ovarian tissue found to be cancerous versus ovarian tissue found to be noncancerous

Correlate the expression of AVP and its V1 receptor to stage of ovarian neoplasms graded by histology assessment

Correlate the expression of AVP and its receptor to intratumoral vascularization through Doppler ultrasound and systemic blood pressure.

Locations

Tripler Army Medical Center, Honolulu, United States

Linked Diseases

Ovarian Neoplasms

Ovarian Neoplasms — a type of gynecological cancer.

Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms